Adrenergic and cholinergic regulation of cortisol secretion from the zona fasciculata/reticularis of bovine adrenal cortex.
Inner zone cells, isolated from bovine adrenal cortex, secrete cortisol in response to both adrenergic and cholinergic agonists. The response to adrenaline (and other catecholamines) appears during culture, is evident by 24 h and reaches a maximum by 48-72 h, but is absent in freshly isolated cells. Pre-incubation of cultured cells with adrenaline leads to homologous desensitisation; the possibility that this may explain the absent response in freshly isolated cells is discussed. Cells show a dose-dependent cyclic AMP response but no increased membrane phosphoinositide turnover. In agreement, cortisol secretion is blocked by beta-receptor, but not alpha-receptor, antagonists. Schild analysis established that the response occurs through binding to a beta 1-receptor subtype, consistent with adrenergic innervation as opposed to an effect of circulating catecholamines. In contrast, cortisol secretion to AcCh was present in both freshly isolated cells and those in culture, reaching a maximum by 48-72 h in culture. The response was specifically blocked by muscarinic, but not nicotinic, antagonists. No effect on cyclic AMP formation was observed, but dose-dependent stimulation of phosphoinositide turnover occurred. HPLC analysis of the time-course of appearance of 3H-inositol labelled head groups (from cells pre-labelled with 3H-inositol) confirmed that AcCh activates a phosphoinositidase C. Intracellular Ca2+ oscillations were also measured from fura-2 loaded single cells in response to AcCh. Together with other pharmacological studies, these observations establish that AcCh acts through a M3 muscarinic receptor subtype in these cells. The possible significance of these findings in vivo is discussed.
Walker
S W
SW
Department of Clinical Chemistry, Royal Infirmary, University of Edinburgh.
Lightly
E R
ER
Clyne
C
C
Williams
B C
BC
Bird
I M
IM
D000109:Acetylcholine / Q000494:pharmacology; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002395:Catecholamines / Q000502:physiology*; D002417:Cattle; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D006854:Hydrocortisone / Q000378:metabolism*; D007294:Inositol / Q000378:metabolism; D010277:Parasympathomimetics / Q000494:pharmacology*; D011941:Receptors, Adrenergic / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D014403:Tubocurarine / Q000494:pharmacology; D015383:Zona Fasciculata / Q000166:cytology / Q000378:metabolism* / Q000648:ultrastructure; D015385:Zona Reticularis / Q000166:cytology / Q000378:metabolism* / Q000648:ultrastructure
D002395:Catecholamines; D010277:Parasympathomimetics; D011941:Receptors, Adrenergic; D000804:Angiotensin II; D007294:Inositol; D001285:Atropine; D000324:Adrenocorticotropic Hormone; D000242:Cyclic AMP; D000109:Acetylcholine; D014403:Tubocurarine; D006854:Hydrocortisone; D004837:Epinephrine